X4 PHARMACEUTIC. DL-001
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally bioavailable selective antagonist of chemokine receptor C-X-C chemokine receptor type 4 (CXCR4) for the treatment of patients with warts, hypogammaglobulinemia, infections, an… Read more
X4 PHARMACEUTIC. DL-001 (48Q) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, X4 PHARMACEUTIC. DL-001 (48Q) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
X4 PHARMACEUTIC. DL-001 - Net Assets Trend (None–None)
This chart illustrates how X4 PHARMACEUTIC. DL-001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for X4 PHARMACEUTIC. DL-001 (None–None)
The table below shows the annual net assets of X4 PHARMACEUTIC. DL-001 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to X4 PHARMACEUTIC. DL-001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
X4 PHARMACEUTIC. DL-001 Competitors by Market Cap
The table below lists competitors of X4 PHARMACEUTIC. DL-001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Atara Biotherapeutics Inc
NASDAQ:ATRA
|
$22.13 Million |
|
Arzum Elektrikli Ev Aletleri Sanayi ve Ticaret AS
IS:ARZUM
|
$22.14 Million |
|
Moulinvest
PA:ALMOU
|
$22.14 Million |
|
Drb Holding
KO:004840
|
$22.14 Million |
|
Chuwa Wool Industry Co Taiwan Ltd
TW:1439
|
$22.11 Million |
|
TS Corp Preference Shares
KO:001795
|
$22.11 Million |
|
YLAB Corporation
KQ:432430
|
$22.10 Million |
|
Fortune Minerals Limited
PINK:FTMDF
|
$22.10 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in X4 PHARMACEUTIC. DL-001's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares X4 PHARMACEUTIC. DL-001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently X4 PHARMACEUTIC. DL-001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares X4 PHARMACEUTIC. DL-001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| X4 PHARMACEUTIC. DL-001 (48Q) | €- | N/A | N/A | $22.13 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |